Serum adiponectin levels in adult growth hormone deficiency and acromegaly

• Published in: Growth hormone & IGF research Vol. 14; no. 6; pp. 449 - 454
• Main Authors: Fukuda, Izumi, Hizuka, Naomi, Ishikawa, Yukiko, Itoh, Emina, Yasumoto, Kumiko, Murakami, Yuko, Sata, Akira, Tsukada, Junko, Kurimoto, Makiko, Okubo, Yumiko, Takano, Kazue
• Format: Journal Article
• Language: English
• Published: Scotland Elsevier Ltd 01.12.2004
• Subjects: Acromegaly; Acromegaly - blood; Adiponectin; Adult; Adult GHD; Aged; Body Mass Index; Female; Human Growth Hormone - blood; Human Growth Hormone - deficiency; Humans; Insulin Resistance; Insulin-Like Growth Factor I - metabolism; Intercellular Signaling Peptides and Proteins - blood; Male; Middle Aged; QUICKI; Reference Values; Acromegaly; Adult GHD; QUICKI; Adiponectin
• ISSN: 1096-6374; 1532-2238
• DOI: 10.1016/j.ghir.2004.06.005

Atherosclerosis and insulin resistance are common complications of adult growth hormone deficiency (GHD) and acromegaly. Circulating adiponectin, an adipocyte-derived protein, has both anti-atherogenic and insulin-sensitising effects. In this study, we measured serum adiponectin levels in patients with either adult GHD or acromegaly to clarify the impact of GH secretory states on the regulation of serum adiponectin levels. Serum adiponectin level was measured by radioimmunoassay in 32 patients with adult GHD, 49 patients with acromegaly and 25 normal subjects. The relationships between adiponectin and insulin sensitivity index assessed as quantitative insulin sensitivity check index (QUICKI), BMI, and serum GH and IGF-I levels were then investigated. The values of QUICKI were significantly lower in patients with acromegaly or adult GHD compared to normal subjects (0.33 ± 0.03, P < 0.01, 0.35 ± 0.04, P < 0.05 and 0.36 ± 0.01, respectively). While patients with adult GHD had significantly lower serum adiponectin levels than patients with acromegaly (6.5 ± 3.9, 9.2 ± 5.0, P < 0.01) these levels were not significantly different from those found in normal subjects (7.8 ± 4.3 μg/ml). There was an inverse correlation between serum adiponectin levels and BMI in both patient groups (GHD r = −0.39, P < 0.05; Acromegaly r = −0.35, P < 0.05). However, serum adiponectin levels correlated positively with QUICKI ( R s = 0.37, P < 0.05) only in patients with adult GHD. In patients with acromegaly, the levels of circulating adiponectin showed an inverse correlation with serum IGF-I levels ( R s = −0.34, P < 0.05), but not with basal GH levels. These results demonstrate that adiponectin levels are significantly lower in patients with adult GHD than in patients with acromegaly. Adiponectin levels are similar in patients with GHD and healthy controls, whereas in patients with acromegaly, insulin resistance appears to be not closely related to adiponectin levels compared with BMI. The different relationship between adiponectin and QUICKI observed in the adult GHD and acromegaly groups presumably reflects differences in the mechanisms of insulin resistance under states of GH deficiency or excess.